Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Desplas
Observed names:
D. Desplas,
David DESPLAS
Institutions:
Conservatoire National des Arts et Métiers,
Agence Nationale de Sécurité du Médicament et des Produits de Santé,
Epi-Phare,
l'Assurance Maladie
Observed institutions:
Conservatoire National des Arts et Métiers,
Agence Nationale de Sécurité du Médicament et des Produits de Santé,
Epi-Phare,
l'Assurance Maladie
ORCID:
0000-0003-1151-3867
Observed ORCID:
0000-0003-1151-3867
OpenAlex ID:
A5071856288
Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study
2022
·
Hugo Jourdain
, Sophie Billioti de Gage
, et al.
·
The Lancet Public Health
·
125
PDF
Roll-out of HIV pre-exposure prophylaxis use in France: A nationwide observational study from 2016 to 2021
2022
·
Sophie Billioti de Gage
, David Desplas
, et al.
·
The Lancet Regional Health - Europe
·
41
Intravitreal Anti–Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic
2020
·
Sophie Billioti de Gage
, Jérôme Drouin
, et al.
·
JAMA Ophthalmology
·
35
PDF
Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
2021
·
Noémie Roland
, Jérôme Drouin
, et al.
·
Contraception
·
26
PDF
Effects of the Coronavirus Disease 2019 (COVID-19) Lockdown on the Use of Contraceptives and Ovulation Inductors in France
2021
·
Noémie Roland
, Jerôme Drouin
, et al.
·
Obstetrics and Gynecology
·
24
Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study
2024
·
H. Jourdain
, A. Di Meglio
, et al.
·
ESMO Open
·
21
Effect of extending PrEP initiation to primary care settings: a nationwide cohort study in France
2025
·
Sophie Bamouni
, Sophie Billioti de Gage
, et al.
·
The Lancet Public Health
·
17
Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study
2022
·
Epiphane Kolla
, Alain Weill
, et al.
·
Vaccines
·
8
PDF
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
2025
·
Hugo Jourdain
, Nicolas Albin
, et al.
·
The Lancet Regional Health - Europe
·
7
PDF
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study
2025
·
Nadia Haddy
, Hugo Jourdain
, et al.
·
BioDrugs
·
7
Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies
2025
·
Hugo Jourdain
, Antonio Di Meglio
, et al.
·
The Lancet Regional Health - Europe
·
6
PDF
Roll-out and effectiveness of HIV pre-exposure prophylaxis in France: An overview
2023
·
Sophie Billioti de Gage
, Hugo Jourdain
, et al.
·
Therapies
·
6
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
2026
·
Aya Elhusseiny Shaaban
, Hugo Jourdain
, et al.
·
British Journal of Cancer
·
5
PDF
Impact of coronavirus disease 2019 on contraception use in France
2023
·
Noémie Roland
, Jérôme Drouin
, et al.
·
Therapies
·
3
Ambulatory artificial nutrition support use in adolescents and adults: A nationwide population‐based descriptive cohort study
2025
·
Claire Rives‐Lange
, David Desplas
, et al.
·
Journal of Parenteral and Enteral Nutrition
·
2
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
2024
·
Hugo Jourdain
, Nicolas Albin
, et al.
·
Clinical and Translational Gastroenterology
·
2
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France
2026
·
Allison Singier
, Stéphane Vignot
, et al.
·
BioDrugs
·
1
PDF
Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France
2026
·
Allison Singier
, Stéphane Vignot
, et al.
·
The Oncologist
PDF
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France
2026
·
Allison Singier
, Stéphane Vignot
, et al.
·
BioDrugs
PDF
Création d’une application interactive d’exploration des données avec l’intelligence artificielle générative : étude de cas sur l’utilisation des anti-PD-(L)1 en France entre 2015 et 2024
2026
·
Hugo JOURDAIN
, David DESPLAS
, et al.
·
Journal of Epidemiology and Population Health
Utilisation en vie réelle et survie de sacituzumab govitecan dans les cancers du sein métastatiques triple-négatif et Hormono-positif /HER2−négatif
2026
·
Aya ELHUSSEINY SHAABAN
, Hugo JOURDAIN
, et al.
·
Journal of Epidemiology and Population Health
Utilisation en vie réelle de l’association dostarlimab-chimiothérapie dans le cancer de l’endomètre avancé ou récidivant
2026
·
Allison SINGIER
, Stéphane VIGNOT
, et al.
·
Journal of Epidemiology and Population Health
Optimisation de la surveillance épidémiologique des produits de santé : de la donnée brute aux rapports standards automatisés
2025
·
Hugo JOURDAIN
, Jérôme DROUIN
, et al.
·
Journal of Epidemiology and Population Health
Trastuzumab deruxtecan versus tucatinib en troisième ligne de traitement du cancer du sein métastatique HER2-positif : une émulation d'essai cible avec le Système National des Données de Santé
2025
·
Hugo JOURDAIN
, Antonio DI MEGLIO
, et al.
·
Journal of Epidemiology and Population Health
Trastuzumab deruxtecan versus trastuzumab emtansine en seconde ligne de traitement du cancer du sein métastatique HER2-positif : une émulation d'essai cible avec le Système National des Données de Santé
2025
·
Hugo JOURDAIN
, Antonio DI MEGLIO
, et al.
·
Journal of Epidemiology and Population Health
Show more works
View as search
Works count:
28
Citation count:
336
H-index:
8
I10-index:
7
Year
Topic
Type